Swansea University
Swansea, sa2 8pp, United Kingdom
NCT Number: NCT05381090
The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive impairment. It will focus on validating pilot data generated following the analysis of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and healthy cohorts (IRAS project ID: 250933). In addition to the advantages of study replication we will extend the analysis to include two further patient groups that are associated with cognitive impairments, namely, Alzheimer's dementia (AD) and dementia with Lewy bodies (DLB). This study will increase confidence in the replication of our findings.
This will be a cross-sectional study using peripheral venous blood.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Swansea, sa2 8pp, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Specific criteria for each group;
Parkinson's Disease
Parkinson's Disease Dementia
Dementia with Lewy Bodies
Alzheimer's Disease
Exclusion criteria
Additional disease specific exclusions;
Parkinson's Disease Dementia exclusion criteria
Dementia with Lewy bodies exclusion criteria
Alzheimer's dementia exclusion criteria
Controls exclusion criteria
Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
Time frame: Through study completion, an average of 1 year
Quantification of circulating ghrelin peptides
Time frame: Through study completion, an average of 1 year
Quantification of circulating ghrelin peptides
Time frame: Through the study, an average of 1 year.
Quantification of Peripheral Blood Mononuclear Cell (PBMC) function, via RNA-assays and protein-immunoassays from control, PD, PDD, DLB and AD donors.
Time frame: Through study completion, an average of 1 year.
Quantification of LEAP2 via immunoassay in blood plasma collected from control, PD, PDD, AD and DLB donors.
Time frame: Through study completion, an average of 1 year.
Quantification of insulin via immunoassay in blood plasma collected from control, PD, PDD, DLB and AD donors.
Time frame: Through the study, an average of 1 year.
Quantification of proteins via Next Generation Sequencing (NGS)-based proteomics.
Swansea University
Other
Acronym: GDEM3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07306065
Alzheimer Disease, Alzheimers Disease
Orlando, Florida, United States
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial Details